[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pheochromocytoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pheochromocytoma":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,47,79,108,134,199,228,267,293,319,347,383,405,455,487,510,534,556,589,614,635,658,680,721,742],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645333","phase-2-an-experimental-study-of-belzutifan-impact-on-catecholamine-metabolism-100645333",false,"NCT07680205","An Experimental Study of Belzutifan Impact on Catecholamine Metabolism","An Experimental Pilot Study to Investigate Changes in Catecholamine Synthesis and Metabolism in Patients With Molecularly Profiled Phaeochromocytoma and Paraganglioma Taking Belzutifan","Inclusion Criteria:\n\n* Adult patients \\> 18 years\n* Patients must have a biochemically confirmed diagnosis of a phaeochromocytoma or paraganglioma using plasma metanephrines or 24- hour urinary metanephrines and plasma or urinary metanephrines should be at least 1.5 times the upper limit of the normal reference range.\n* Female patients of child-bearing potential must have a negative serum pregnancy test result within 3 days before first administration of study drug\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Has hypoxia, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen.\n* Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass graft surgery (CABG) ≤6 months from Day 1 of study drug administration, or New York Heart Association Class III or IV congestive heart failure. Medically controlled arrhythmia stable on medication is permitted.\n* Has a co-existing malignancy (in addition to PPGL)\n* Has a Hb \\\u003C 100g\u002FdL\n* Is on medications which may interfere with belzutifan pharmacokinetics and that cannot be stopped for the duration of the study and for 7 days after the study period (everolimus, omeprazole, esomeprazole, Fluconazole, fluoxetine, Voriconazole, Sirolimus)\n* Has a known diagnosis of HIV, hepatitis B or hepatitis C","ALL",{"count":19,"type":20},12,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'. The study aims to identify changes in the production and metabolism of catecholamines by measuring the substance which starts the chain of catecholamine metabolism called tyrosine in patients before, during and after 5 days of taking Belzutifan 120mg daily.",[26,27,28,29,30],"Pheochromocytoma and Paraganglioma (PPGL)","Pheochromocytoma Malignant","Pheochromocytoma, Metastatic","Pheochromocytoma\u002FParaganglioma","Pheochromocytoma",[32,33],"Belzutifan","catecholamine synthesis","RECRUITING","2026-06-29",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2026-04-27",{"date":42,"type":20},"2027-12",{"name":44,"class":45},"Cambridge University Hospitals NHS Foundation Trust","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":46},"100548961","phase-1-somatostatin-receptors-sstr-agonist-212pbvmt-alpha-net-in-metastatic-or-inoperable-sstr-gastrointestinal-neuroendocrine-tumor-and-pheochromocytomaparaganglioma-previously-treated-with-systemic-targeted-radioligand-therapy-100548961","NCT06427798","Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma\u002FParaganglioma Previously Treated With Systemic Targeted Radioligand Therapy","Phase I\u002FII Trial of Systemic Targeted Radioligand Therapy (TRT) With Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma\u002FParagangliomas Previously Treated With Systemic Radioligand Therapy","* INCLUSION CRITERIA:\n* Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET) or pheochromocytoma\u002Fparaganglioma (PPGL) cancers that are metastatic or inoperable per Standard of Care.\n* Have received at least 1 prior systemic radioligand therapy for definitive therapeutic purposes. Note: Participants with prior external beam radiation treatment (EBRT) will also be eligible as long as they have had at least 1 prior administration of a systemic radioligand therapy.\n* Must have at least 1 measurable lesion by RECIST 1.1 (phase II only).\n* History of progression by imaging per RECIST 1.1 or clinically (defined as increase in severity or frequency of symptoms related to disease) within the past 36 months prior to the first dose of \\[203Pb\\]VMT-alpha-NET.\n* Evidence of somatostatin receptors (SSTR) expression on at least 50 percent of the radiographically identifiable (i.e., visible on an anatomic scan such as CT or magnetic resonance imaging \\[MRI\\]) tumor, as indicated by a positive (uptake qualitatively identifiable as above the local background) on SSTR PET scan.\n* Age \\>= 18 years.\n* ECOG performance status \\\u003C= 1.\n* Participants must have adequate organ and marrow function as defined below:\n\n  * Leukocytes: 3,000\u002Fmicroliter\n  * Absolute Neutrophil Count: 1,500\u002Fmicroliter\n  * Platelets: 100,000\u002Fmiroliter\n  * Hemoglobin: \\>= 9.0 g\u002FdL\n  * Total bilirubin: within normal institutional limits. Note: \\\u003C= 5 X institutional upper limit of normal (ULN) if bilirubin elevation is due to a benign process such as Gilbert syndrome\n  * AST: \\\u003C= 2.5 X institutional ULN\n  * ALT: \\\u003C= 2.5 X institutional ULN\n  * Creatinine: within normal institutional limits\n\nOR\n\n* Calculated creatinine clearance (glomerular filtration rate (eGFR): \\>= 60 mL\u002Fmin\u002F1.73 m\\^2 for participants with creatinine levels above institutional normal\n\n  * Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression at screening.\n  * Participants with new or progressive brain metastases or leptomeningeal disease are eligible as long as the participant is asymptomatic and not requiring medication for symptom control from the brain lesions at screening.\n  * Participants seropositive for human immunodeficiency virus (HIV) must:\n* be on effective anti-retroviral therapy; and\n* have an undetectable viral load at screening.\n* Participants seropositive for hepatitis B virus (HBV), must have HBV viral load undetectable at screening.\n\n  -Participants seropositive for hepatitis C virus (HCV) must:\n* received curative treatment; and\n* have an undetectable HCV viral load at screening.\n\n  * Participants may enroll in this study while on another therapeutic trial in order to start the screening process. However, all other investigational agents should be stopped at least 28 days prior to receiving \\[203Pb\\]VMT-alpha-NET.\n  * Individuals of child-bearing potential (IOCBP) and individuals who can father children must agree to use an effective method of contraception (barrier, hormonal, intrauterine device \\[IUD\\], surgical sterilization, abstinence) at study entry and at least 6 months after the last dose of the study agent(s).\n  * Nursing participants must be willing to discontinue nursing from study treatment initiation through 6 months after the last dose of the study agents.\n  * The ability of the participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to VMT-alpha-NET.\n* Positive Beta human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test performed in i IOCBP at screening.\n* QTc \\> 450 ms on electrocardiogram (EKG) at screening. Note: Framingham correction for QTc will be used.\n* History of or detection at screening of active\u002Funtreated secondary malignancy except nonmelanoma skin cancer and carcinoma in situ of the uterine cervix.\n* Uncontrolled intercurrent illness, factors, evaluated by medical history and physical exam which would potentially increase in the risk of the participant.","18 Years","120 Years",{"count":57,"type":20},66,[59,23],"PHASE1","Background:\n\nGastrointestinal neuroendocrine tumors (GI NET) are a type of cancer that affects the stomach and intestines; pheochromocytoma\u002Fparagangliomas (PPGL) are tumors that grow in or near the adrenal glands. Both of these types of tumor have high levels of a protein called somatostatin receptors (SSTR) on their surfaces. Researchers want to test a treatment that targets SSTR.\n\nObjective:\n\nTo test a drug (\\[212Pb\\]VMT-alpha-NET) in people with GI NET or PPGL. The drug has 2 components: a protein to bind to SSTR and a radioactive agent to kill the cancer cells.\n\nEligibility:\n\nAdults aged 18 years or older with GI NET or PPGL tumors that have spread and cannot be removed with surgery.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam, with imaging scans, blood tests, and tests of their heart function.\n\n\\[212Pb\\]VMT-alpha-NET is given through a tube attached to a needle inserted into a vein (infusion). Treatment will be given in four 8 week cycles. Participants will receive the drug on the first day of each cycle. They will remain in the clinic at least 4 hours after each infusion and may need to stay in the hospital for up to 48 hour for monitoring and testing. They will have blood tests every week of each cycle.\n\nSome participants will also get a related study drug (\\[203Pb\\]VMT-alpha-NET). They will receive this drug a few days before the first 2 cycles. At 4, 24, and 48 hours after each infusion, they will have whole body scans. These scans will show where the study drug went in their body.\n\nFollow-up visits will continue for 10 years....",[62,63,30,64],"Somatostatin Receptor Positive","Gastrointestinal Neuroendocrine Tumors","Paragangliomas",[66,67,68,69],"212Pb","Targeted Therapies","Image-Guided Dosimetry","VMT- -NET","2026-06-26",{"date":35,"type":38},{"date":73,"type":38},"2025-02-07",{"date":75,"type":20},"2039-07-01",{"name":77,"class":78},"National Cancer Institute (NCI)","NIH",{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":55,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":46},"100057209","phase-1-diagnosis-of-pheochromocytoma-100057209","NCT00004847","Diagnosis of Pheochromocytoma","Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma","* INCLUSION CRITERIA:\n\nPatients are eligible for inclusion in this study if they are adults or children of age 3 years old and up with known, sporadic or familial PHEO\u002FPGL, on the basis of one or more of the following:\n\n1. High levels of blood or urinary catecholamines, metanephrines, methoxytyramine or chromogranin A.\n2. Highly suspected presence of PHEO\u002FPGL based on imaging studies, even with normal biochemistry.\n3. Personal or family history of PHEO\u002FPGL or genetic pathogenic variants known to predispose individuals to develop PHEO\u002FPGL.\n\nSigned informed consent is required. The informed consent may be signed by the patient, parent\u002Fguardian in pediatric patients or legally authorized representative (LAR) in adults who lack-decision making capacity to consent to research participation.\n\nPatients must have an outside general practitioner or endocrinologist. Patients with metastatic disease must also have an outside oncologist.\n\nFamily Members of Patients Arm (Linkage Analysis)\n\nParticipants are eligible for inclusion in this study arm if they are:\n\n* Adult family members of patients enrolled in this study;\n* The index family member in this study has a suspected hereditary PHEO\u002FPGL based on previous genetic testing and other suspicious hereditory patterns such as family history of multiple individuals with PHEO\u002FPGL; early age of disease onset; multiplicity of primary tumors; recurrence, etc. and\n* Signed informed consent form is required\n\nEXCLUSION CRITERIA:\n\nPotential patients will be excluded on the basis of one or more of the following:\n\n1. Pregnant or breastfeeding women\n2. Severe cardiac dysfunction\n3. Currently on dialysis\n\nA pregnancy test is performed in women of childbearing age (up to age 55) as a screening after consenting. If a patient is found to have a positive pregnancy test, her participation in this protocol will be terminated. The patient can enroll or re-enroll in the protocol when she is no longer pregnant or breastfeeding.\n\nIn-person participating patients who are not willing to return to the NIH (e.g., after surgery or an initial evaluation) for more than 2 years may be removed from the protocol.\n\nSPECIFIC INCLUSION\u002FEXCLUSION CRITERIA FOR IMAGING STUDIES WITHIN OUR PROTOCOL:\n\nIn adult patients (Excludes Linkage Analysis Arm)\n\nImaging studies are not done in patients that have the following exclusion criteria:\n\n* Inability to lie still for the entire imaging time (e.g., cough, severe arthritis, etc.).\n* Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (e.g., severe claustrophobia, radiation phobia, etc.)\n* Any additional medical conditions, serious illness, or other extenuating circumstance that, in the opinion of the Principal Investigator, may significantly interfere with study compliance.\n\nIn pediatric patients:\n\nInclusion criteria for research PET imaging in children:\n\n* Children over 10 years old with very high suspicion of sporadic or familial PHEO\u002FPGL based on at least one of the following:\n\n  * The presence of new onset of symptoms typical of PHEO\u002FPGL such as hypertension or hypertensive episodes, sweating, headaches, pallor, palpitations, drug resistant hypertension, etc.\n  * Family history of PHEO\u002FPGL or genetic pathogenic variants known to predispose individuals to develop these tumors.\n  * The presence of a tumor on conventional imaging including ultrasound, CT and\u002For MRI or \\[123I\\]-MIBG or PET imaging not limited to \\[18F\\]-FDG.\n* Children must give informed assent and be willing to return to the NIH for follow-up.\n\nExclusion criteria for research PET imaging in children:\n\n* Children of less than 10 years of age.\n* Children with impaired mental capacity that precludes informed assent.\n* Inability to lie still for the entire imaging time (e.g., cough, turbulent children, severe claustrophobia, etc.).","3 Years",{"count":88,"type":20},3000,[59],"The goal of this study is to develop better methods of diagnosis, localization, and treatment for pheochromocytomas. These tumors, which usually arise from the adrenal glands, are often difficult to detect with current methods. Pheochromocytomas release chemicals called catecholamines, causing high blood pressure. Undetected, the tumors can lead to severe medical consequences, including stroke, heart attack and sudden death, in situations that would normally pose little or no risk, such as surgery, general anesthesia or childbirth.\n\nPatients with pheochromocytoma may be eligible for this study. Candidates will be screened with a medical history and physical examination, electrocardiogram, and blood and urine tests. Study participants will undergo blood, urine, and imaging tests, described below, to detect pheochromocytoma. If a tumor is found, the patient will be offered surgery. If surgery is not feasible (for example, if there are multiple tumors that cannot be removed), evaluations will continue in follow-up visits. If the tumor cannot be found, the patient will be offered medical treatment and efforts to detect the tumor will continue. Main diagnostic and research tests may include the following:\n\n1. Blood tests - mainly measurements of plasma or urine catecholamines and metanephrines as well as methoxytyramine. If necessary the clonidine suppression test can be carried out.\n2. Standard imaging tests - Non-investigational imaging tests include computed tomography (CT), magnetic resonance imaging (MRI), sonography, and 123I-MIBG scintigraphy and FDG (positron emission tomography) PET\u002FCT. These scans may be done before and\u002For after surgical removal of pheochromocytoma.\n3. Research PET scanning is done using an injection of radioactive compounds. Patients may undergo 18F-FDOPA, 18F-DA, as well as 68Ga-DOTATATE PET\u002FCT . Each scan takes up to about 2 hours.\n4. Genetic testing - A small blood sample is collected for DNA analysis and other analyses.",[30,92,93],"Endocrine Disease","Endocrine Diseases",[95,96,97,98],"Genetics","Metanephrines","PET","Catecholamines","2026-06-17",{"date":101,"type":38},"2026-06-18",{"date":103,"type":38},"2000-03-22",{"date":105,"type":20},"2048-11-30",{"name":107,"class":78},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":46},"100641367","phase-1-211at-mabg-in-adults-with-advanced-neuroendocrine-cancers-100641367","NCT07661420","211At-MABG in Adults With Advanced Neuroendocrine Cancers","Inclusion Criteria:\n\n1. Adult patients, at least 18 years of age\n2. Advanced neuroendocrine cancers requiring systemic therapy and refractory to, ineligible for, declining, or lacking standard treatments.\n3. I MIBG imaging indicating MIBG-avid disease (radiotracer uptake above background in at least one tumor site) per Investigator\u002FSub-Investigator assessment.\n4. Participants must provide written informed consent prior to study-specific procedures.\n5. ECOG performance status ≤ 2.\n6. Adequate organ function including:\n\n   1. Hemoglobin ≥ 9 g\u002FdL\n   2. Absolute neutrophil count ≥ 1,500\u002Fmm³\n   3. Platelet count ≥ 75,000\u002Fmm³\n   4. Measured or estimated GFR ≥ 60 mL\u002Fmin\n   5. Serum bilirubin ≤ 1.5x upper limit of normal\n   6. ALT\u002FAST each ≤ 2.5x upper limit of normal\n7. Life expectancy at least 3 months as judged by treating physician\n\nExclusion Criteria:\n\n1. Women who are pregnant or breast-feeding will not be eligible for this study.\n2. Inability to tolerate study procedures in the opinion of the investigator or treating physician.\n3. Serious or unstable medical, psychological, or social conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.\n4. Uncontrolled brain metastasis (Participant must be at least 4 weeks since CNS-directed therapy and no longer requiring corticosteroid therapy).\n5. Anticancer therapy, except hormonal therapy or bone supportive therapies, within 14 days of cycle 1 day 1.\n6. Has a known additional malignancy (other than the disease under study) that has required active systemic treatment within the past 2 years AND for which the natural history or recent\u002Fongoing treatment could likely interfere with study endpoints or safety of the study treatment per Investigator and Medical Director assessment.",{"count":115,"type":20},16,[59],"Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma \u002F paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).",[30,119,120,121,122,123],"Paraganglioma","Neuroendocrine Tumors","Medullary Thyroid Cancer","Bronchial Carcinoid","Gastroenteropancreatic Neuroendocrine Neoplasm","NOT_YET_RECRUITING","2026-06-16",{"date":127,"type":38},"2026-06-22",{"date":129,"type":20},"2026-08-01",{"date":131,"type":20},"2032-08-01",{"name":133,"class":45},"University of Pennsylvania",{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":166,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":46},"100562786","phase-1-study-in-children-and-adolescents-of-177lu-dotatate-lutathera-combined-with-the-parp-inhibitor-olaparib-for-the-treatment-of-recurrent-or-relapsed-solid-tumours-expressing-somatostatin-receptor-sstr-luparped-100562786","NCT06607692","Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).","Single-arm Open-label Phase I\u002FII Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).","LUPARPED","Inclusion criteria:\n\n* 18 months - 18 years of age at the time of the initial diagnosis.\n* ≥ 3 years at the moment of inclusion in the trial.\n* Diagnosis: relapsed\u002Frefractory solid tumours with positive uptake on SSTR-PET (PET-CT or PET-MRI), performed in the previous three months before entering the study.\n\nThe evaluation of SSTR expression will be classified according to a qualitative 4-point scale: SSTR expression V (visual score):\n\n* Score = 0: Below or equal to blood pool\n* Score = 1: Above blood pool and lower than liver\n* Score = 2: Equal to or above liver and lower than spleen\n* Score = 3: Equal to or above spleen\n\nPatients with scores ≥ 2 in the majority of the tumoral lesions will be considered to have a positive SSTR-PET and will be therefore eligible for the trial. Patients with a higher score are presumed to have a better response to the treatment.\n\nIt is admissible to have non-measurable disease only (e.g., HR-NB with bone-only or bone-marrow-only active disease).\n\n* Performance status ≥ 50% according to Lansky scale (\\\u003C16 years old) or Karnofsky scale (for ≥16 years old).\n* Life expectancy of at least 3 months.\n* Availability of ability to swallow tablets or capsules.\n* Adequate organ function within 28 days prior to enrolment, as defined by:\n\n  * Hb ≥10 g\u002Fdl (packed red blood transfusion is acceptable up to 24 hours prior starting treatment);\n  * White blood cell (WBC) count ≥ 2500\u002FμL (equivalent to 2.5 x 109\u002FL)\n  * Absolute Neutrophil Count (ANC) ≥ 1000\u002Fμl;\n  * Platelets ≥ 100.000\u002Fμl, without transfusion in the prior ≥7 days;\n  * Serum plasma creatinine ≤ 1.5 x upper limit of normal (ULN) OR estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin\u002F1.73m2 (assessed by 2009-Schwartz formula).\n  * Total bilirubin ≤ 1.5 x the institutional ULN. For patients with known Gilbert's Syndrome ≤ 3.0 ULN is permitted.\n  * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 3.0 ULN.\n  * Albumin \\>3.0 g\u002FdL (3.0 g\u002FdL is equivalent to 30 g\u002FL)\n* A negative serum or urine pregnancy test in women with onset of menses or ≥12 years of age.\n* Patients of reproductive potential must agree to use highly effective contraceptive methods for the entire study duration and up to 7 months, in case of females, and 4 months in case of males, after the last dose of Lutathera, or up to 6 months, in case of females, and 3 months in case of males, after the last dose of olaparib, whichever takes places later.\n* Have the ability to comprehend and willingness to provide written informed consent (ICF) for the study before patient registration or any trial-related screening procedures. If the patient is \\\u003C18 years old, the written informed consent must be signed by the parent(s) or legal guardian(s) according to national regulations. In the case of patients between 12 and 17 years, they must sign an assent form, and if the patient turns 18 during their participation in the study, they must sign an informed consent form.\n* Adequate recovery from major surgery prior to receiving study treatment.\n* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.\n\nExclusion criteria\n\n* Previous significant drug-induced hepatitis toxicity experienced in the past that has required treatment dose reductions, treatment discontinuation or that, at the investigator discretion, could infer a risk.\n* Having received more than one previous treatment with other radiolabelled somatostatin analogues.\n* Inability to swallow tablets or capsules.\n* Subjects who are currently receiving any other anticancer and\u002For investigational agents (e.g. chemotherapy, immunotherapy or biological therapy \\[including monoclonal antibodies\\]). There must be at least 28 days of washout from any prior treatment. In case of checkpoints inhibitors, there should be at least 4 months of washout. Palliative Radiation Therapy for symptom control (e.g. pain relief) could be acceptable, at the discretion of the investigator.\n* Treatment with long-acting somatostatin analogues within 28 days prior the administration of 177Lu-DOTATATE.\n* Known hypersensitivity to any of the excipients.\n* Subjects who have an uncontrolled infection.\n* Lactating women.",{"count":7,"type":20},[59,23],"Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)",[146,147,148,149,150,119,30,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165],"Solid Tumor Cancer","Medulloblastoma","High Risk Neuroblastoma","High Grade Gliomas","Meningioma","Neuroendocrine Tumours (NET)","Adrenal Tumours","DIPG","Glioblastoma","Glioblastoma (GBM)","Osteosarcoma Recurrent","Carcinoma Adrenal","Synovial Sarcomas","Esthesioneuroblastoma","Neuroblastoma Recurrent","Solid Tumor Refractory to Conventional Treatment","Medulloblastoma Recurrent","Paraganglioma\u002F Phaeochromocytoma","Ependymoma","Ependymoma Recurrent",[167,168,169,170,171,172,173,174,175,176,177,178,179,153,180,181,182,183,184,185,186,187,188,164,189],"solid tumours","somatostatin receptors","SSTR","LUTETIUM","OLAPARIB","MEDULLOBLASTOMA","NEUROBLASTOMA","HIGH GRADE GLIOMA","MEININGIOMA","PARAGANGLIOMA","PHEOCHROMOCYTOMA","NEUROENDOCRINE TUMOURS","ADRENAL TUMOR","GLIOBLASTOMA","OSTEOSARCOMA","CARCINOMA ADRENAL","SYNOVIAL SARCOMA","ESTHESIONEUROBLASTOMA","RECURRENT","RELAPSED","RELAPSE","REFRACTORY","Ependimoma Recurrent","2026-06-02",{"date":192,"type":38},"2026-06-04",{"date":194,"type":38},"2024-09-20",{"date":196,"type":20},"2029-12",{"name":198,"class":45},"Fundación de investigación HM",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":17,"minAge":206,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":209,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":46},"100065755","phase-2-iodine-i-131-metaiodobenzylguanidine-in-treating-patients-with-recurrent-progressive-or-refractory-neuroblastoma-or-malignant-pheochromocytoma-or-paraganglioma-100065755","NCT00107289","Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma","Open Access Protocol of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors","Inclusion criteria for NB:\n\n* Patients must have the diagnosis of NB in accordance with the International Criteria, i.e., either histopathology (confirmed by the MSKCC Department of Pathology) or BM involvement plus elevated urinary catecholamines.\n* Must have a history of tumor progression or recurrence or failure to achieve complete response with standard therapy.\n* Patients must have MIBG-avid NB and evaluable disease on MIBG scan at time of enrollment on protocol\n* Prior Therapy: At least 2 weeks should have elapsed since any biologic therapy. Three weeks should have elapsed since last dose of chemotherapy.\n* Age \\>1 year\n* Determination that radiation safety restrictions during therapy period can be implemented.\n* Stem cells: Patients for high does must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment. Patients for low dose do not require cryopreserved autologous hematopoietic stem cell product available. The minimum dose for peripheral blood stem cells is 2 X106 CD34+ cells\u002Fkg.\n* Minimum life expectancy of eight weeks\n* Signed informed consent indicating awareness of the investigational nature of this program.\n\nInclusion criteria for malignant CCT:\n\n* Patients must have the diagnosis of malignant CCT i.e. malignant pheochromocytoma or malignant paraganglioma\n* Patients must have MIBG-avid malignant CCT and evaluable disease on MIBG scan at time of enrollment on protocol\n* Prior Therapy: At least 2 weeks should have elapsed since any biologic therapy. Three weeks should have elapsed since last dose of chemotherapy.\n* Age between 1 and 21 years and able to cooperate with radiation safety restrictions during therapy period\n* Stem cells: Patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment. The minimum dose for peripheral blood stem cells is 2 X106 CD34+ cells\u002Fkg.\n* Minimum life expectancy of eight weeks.\n* Signed informed consent indicating awareness of the investigational nature of this program.\n\nExclusion Criteria:\n\n* Severe major organ toxicity. Specifically, renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less. A grade 3 hearing deficit is acceptable.\n* Active serious infections not controlled by antibiotics.\n* Pregnant women are excluded for fear of danger to the fetus. Therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is used during the study period.\n* Inability or unwillingness to comply with radiation safety procedures or protocol requirements.","1 Year",{"count":208,"type":20},200,[23],"The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.",[212,30],"Neuroblastoma",[214,215,216,217,218],"metastatic pheochromocytoma","recurrent pheochromocytoma","regional pheochromocytoma","recurrent neuroblastoma","04-148","2026-05-28",{"date":221,"type":38},"2026-05-29",{"date":223,"type":38},"2006-05",{"date":225,"type":20},"2027-05",{"name":227,"class":45},"Memorial Sloan Kettering Cancer Center",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":21,"phases":238,"briefSummary":239,"conditions":240,"keywords":245,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":266},"100488169","phase-1-targeted-alpha-particle-therapy-for-advanced-somatostatin-receptor-type-2-sstr2-positive-tumors-100488169","NCT05636618","Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","A Phase I\u002FIIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors","Inclusion Criteria:\n\n1. Adult (ages ≥18) PRRT-naïve subjects with NETs or meningioma by local pathology.\n2. Disease described clinically as: (a) Locally advanced\u002Funresectable or metastatic NETs for dose-finding part of the study (b) Locally advanced\u002Funresectable or metastatic GEP-NETs, bronchial NETs, pheochromocytoma, or paragangliomas for the dose-expansion part of the study (c) Requiring at least 1 prior surgery (resection\u002Fbiopsy) and a maximum of 1 line of EBRT, if technically feasible, for meningioma.\n3. For meningioma: histologically confirmed diagnosis of meningioma, i.e., all grades (1 to 3) per World Health Organization Classification of Tumors of the Central Nervous System (5th edition; WHO-CNS5)\n4. Radiological evidence of measurable disease by: (a) For NETs: RECIST v1.1 criteria on CT with contrast or MRI of the areas of tumor involvement within 60 days of enrollment.\n5. Lesions must have shown radiological evidence of disease progression in the 12 months prior to enrollment. (b) For meningioma: RANO meningioma criteria on contrast-enhanced skull MRI for meningioma within 3 weeks prior to enrollment.\n6. Demonstration of lesional SSTR expression: (a) For NETs: using an FDA-approved somatostatin receptor PET imaging agent, e.g. \\[68Ga\\]DOTATATE, \\[64Cu\\]DOTATATE, or \\[68Ga\\]DOTATOC (b) For meningioma: using a standard-of-care SSTR PET imaging agent within 45 days of enrollment\n7. ECOG Performance Status ≤ 1.\n8. Subjects with HIV positivity are allowed if CD4 Count \\> 350 cells\u002FμL.\n9. Concurrent Somatostatin Analog (SSA) Therapy use while on protocol therapy is allowed provided that the subject must be able to tolerate withholding long-acting SSA therapy for a minimum of 28 days and short-acting SSA therapy for a minimum of 24 hours before the first and subsequent administrations of \\[203Pb\\]VMT-α-NET or \\[212Pb\\]VMT-α-NET\n10. For NETs: Progressive Disease on approved therapies other than radionuclide therapy.\n11. For subjects with meningioma who are receiving corticosteroid treatment, the dose must be ≤ 4 mg\u002Fday dexamethasone (or other corticosteroid equivalent dose) for a minimum of 7 days before the initiation of study treatment.\n12. Must have clinically demonstrated adequate catecholamine blockade if catecholamine-secreting pheochromocytoma\u002Fparaganglioma tumors are present.\n13. Able to understand and sign informed consent and comply with all study requirements.\n14. Life expectancy \\> 3 months.\n15. Satisfactory organ function as determined by laboratory testing.\n16. For females of reproductive potential: agree to use of highly effective contraception and refrain from donating eggs (ova, oocytes) for the purpose of reproduction starting from screening, during treatment, and for at least 6 months after the last dose of \\[212Pb\\]VMT-α-NET\n17. For males of reproductive potential: agree to use of condoms or other methods to ensure effective contraception with partner and refrain from donating sperm starting from screening, during treatment, and for at least 6 months after the last dose of \\[212Pb\\]VMT-α-NET\n\nExclusion Criteria:\n\n1. Known hypersensitivity to SSA, SSTR imaging agents or any of the excipients of \\[212Pb\\]VMT-α-NET.\n2. Known additional malignancy that is progressing or requires active treatment.\n3. Pregnancy or breastfeeding a child.\n4. Febrile illness within 48 hours of any scheduled \\[212Pb\\]VMT-α-NET administration should be rescheduled \\> 48 hours after resolution of fever\\].\n5. Treatment with another investigational medicinal product within 30 days of anticipated treatment.\n6. Prior treatment with systemic PRRT based therapies (i.e., \\[90Y\\] DOTATATE\u002FDOTATOC or \\[177Lu\\] DOTATATE)\n7. Prior treatment with 90-Yttrium radioembolization must be completed at least 6 months prior to enrollment.\n8. External beam radiation therapy (EBRT) must be completed at least 30 days prior to enrollment.\n9. Subjects who have received prior treatment with 90Y radioembolization or EBRT should have radiation absorbed dose to critical organs documented.\n10. Prior treatment with systemic anticancer therapy must be completed at least 30 days prior to enrollment (except for SSAs in subjects with functional tumors).\n11. Major surgery must be completed at least 30 days prior to enrollment.\n12. For Subjects with NETs: Known brain metastases; unless these metastases have been treated and stabilized 6 months prior to enrollment and the subject has been off steroid support for at least 14 days prior to enrollment.\n13. Recently diagnosed and active infections requiring a time-limited course of antifungals or antibiotics in the 3 days prior to enrollment.\n14. Receipt of live attenuated vaccines in the 7 days prior to enrollment.\n15. Grade 3 nausea\u002Fvomiting or diarrhea within 72 hours before the of first scheduled dose of \\[212Pb\\]VMT-α-NET despite adequate antiemetic and other supportive care\n16. Known medical condition which would make this protocol unreasonably hazardous for the subject.\n17. Medical history of a condition resulting in a severe allergic reaction such as anaphylaxis or angioedema to known components of the Investigational Medicinal Product or excipients.\n18. Current abuse of alcohol or illicit drugs (exclusive of use of medically prescribed cannabinoids).\n19. Existence of any medical or social issues likely to interfere with study conduct or that may cause increased risk to the subject or to others, e.g., lack of ability to follow radiation safety precautions.\n20. QTc \\> 450 milliseconds for males and females.","90 Years",{"count":237,"type":20},300,[59,23],"This study is Phase I\u002FIIa First-in-Human Study of \\[212Pb\\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors",[241,242,243,244,119,30,150],"Neuroendocrine Tumors Unresectable","Neuroendocrine Tumor Metastatic","Gastroenteropancreatic Neuroendocrine Tumor","Bronchial Neuroendocrine Tumor",[246,247,120,248,249,250,251,252,253,254,255,150],"Radiopharmaceuticals","Somatostatin Receptor Type 2 (SSTR2)","Metastatic Neuroendocrine Tumors","Pb-212","Theranostics","Alpha Particle Therapy","Radiotherapy","[212Pb]VMT-α-NET","VMT-α-NET-T01","Pb-203","2026-05-13",{"date":258,"type":38},"2026-05-14",{"date":260,"type":38},"2023-09-27",{"date":262,"type":20},"2029-12-26",{"name":264,"class":265},"Perspective Therapeutics","INDUSTRY",19,{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":277,"phases":4,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":46},"100107943","adrenal-tumors---pathogenesis-and-therapy-100107943","NCT00669266","Adrenal Tumors - Pathogenesis and Therapy","Investigation of the Tumorigenesis of Adrenal Tumors and Evaluation of New Therapeutic Options - Untersuchungen Zur Tumorgenese Von Nebennierentumoren Und Evaluation Neuer Therapieoptionen","Inclusion Criteria:\n\n* adrenal tumor detected by imaging\n\nExclusion Criteria:","100 Years",{"count":276,"type":20},500,"OBSERVATIONAL","The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates different therapeutic options in patients with adrenocortical carcinoma.",[280,281,282,283,30],"Adrenal Tumors","Adrenocortical Carcinoma","Cushing Syndrome","Conn Syndrome","2026-05-01",{"date":286,"type":38},"2026-05-07",{"date":288,"type":38},"2002-09",{"date":290,"type":20},"2032-12",{"name":292,"class":45},"University of Wuerzburg",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":274,"enrollmentInfo":299,"targetDuration":4,"studyType":21,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":46},"100301589","phase-2-lu-177-dotatate-lutathera-in-therapy-of-inoperable-pheochromocytoma-paraganglioma-100301589","NCT03206060","Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma\u002F Paraganglioma","* INCLUSION CRITERIA:\n* Surgically inoperable participants with clinical diagnosis of PHEO\u002FPGL who also have demonstrated disease histologically consistent with pheochromocytoma or paraganglioma (preferably confirmed by research site pathology review if initial pathology was done outside of research site, but not mandatory)\n* Progressive disease by RECIST 1.1 with or without symptoms within the last 12 months. NOTE: Untreated participants with existing histologic diagnoses are eligible if progression can be demonstrated\n* PHEO\u002FPGL that is not associated with any known susceptibility genetic mutations for PHEO\u002FPGL except SDHx mutation (a.k.a. \"apparent sporadic\"), based on documented genetic testing results obtained prior to study enrollment. PHEO\u002FPGL that is associated with non-SDHx mutations such as VHL, NF1, and RET will not be eligible for this study.\n* Both metastatic and inoperable primary-only participants are eligible.\n* Must have presence of SSTR+ disease as documented by positive Ga-68-DOTATATE PET scan within 12 weeks of anticipated treatment.\n\nNOTE:\n\n* Positivity of Ga-68-DOTATATE PET scan defined as having at least one lesion that is greater than or equal to 10 mm in diameter with uptake that is higher than or equal to liver and is qualitatively higher and distinguishable from background activity.\n* Measurable disease as defined by RECIST 1.1.\n\n  * Age greater than or equal to 18\n  * Karnofsky Performance Score greater than or equal to 60 or ECOG Performance Status of 2 or better.\n  * Able to understand and willing to sign informed consent.\n  * Ability and willingness to obtain all required scans per study schedule.\n  * Negative serum pregnancy test for women of child-bearing potential. NOTE: A female is not of childbearing potential if a prior history of hysterectomy with bilateral oophorectomy or other procedure has rendered the participant surgically sterile, or \\>2 years since last menstruation.\n  * Female participants of childbearing potential and male participants who are not surgically sterile or with female partners of childbearing potential must agree to use effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal gel) prior to study entry, for the duration of study participation, and for 4 months for male participants or 7 months for female participants (10 half-lives of Lu-177) after the last dose of Lu-177-DOTATATE.\n  * Must have outside endocrinologist\u002Fmedical oncologist who can follow the participant after receiving PRRT (NIH only requirement).\n  * Patients with secreting tumors must be receiving adequate pharmacologic catecholamine blockade as determined by the treating physician.\n  * Ineligible, unable to or unwilling to receive standard first line therapy for PHEO\u002FPGL.\n\nEXCLUSION CRITERIA:\n\n* Creatinine clearance \\\u003C50 mL\u002Fmin calculated by the MDRD method, eventually confirmed by measured creatinine clearance (or measured glomerular filtration rate (GFR) using plasma clearance methods.\n* Serum albumin less than or equal to 3.0 g\u002FdL unless prothrombin time is within the normal range.\n* Liver dysfunction as evidenced by Child s Class C Liver Disease or worse Alternatively, AST or ALT \\> 2.5 times institutional upper limit of normal (ULN) unless liver metastases are present, in which case up to 5 times ULN would be allowed.\n* Hb \\\u003C 8.0 g\u002FdL; WBC \\\u003C 2.0 x 10\\^9\u002FL (or Absolute Neutrophil Count \\\u003C 1000); Platelets \\\u003C 100 x 10\\^9\u002FL\n* In participants with symptoms of congestive heart failure, New York Heart Association (NYHA) classification of grade III or IV\n* Pregnancy or lactation.\n* Prior anti-tumoral radionuclide therapy with unsealed sources. Prior therapy with sealed radioactive sources such as brachytherapy will be allowed.\n* Prior local radiation therapy would be allowed as long as there is at least one non-irradiated index lesion.\n* Known brain metastases, unless these metastases have been treated and stabilized for at least 24 weeks, prior to enrollment in the study. Patients with a history of brain metastases must have a head CT or MRI scan with contrast to document stable disease for at least 24 weeks prior to enrolment in the study.\n* Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for 5 years.\n* Patients who participated in any therapeutic clinical study with an investigational agent within the last 30 days.\n* Patients may be on somatostatin analogue therapy (e.g. but not only limited to sandostatin or lanreotide therapy). However, therapy with somatostatin analogues should not be initiated or altered within 3 months of study enrolment. Patients on short term octreotide may have dose held for 24 hours prior to Lu-177-DOTATATE therapy. Those on long acting octreotide therapy will receive treatment at 1 to 5 days prior to their next cold octreotide dose, in order to prevent competition for the receptor.\n* Patient weight \\> 400 lbs (table limit for PET scanner) or per local institutional standard for participating sites.\n* Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, hypertension (\\>180\u002F110), arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Inability to tolerate at least one modality of diagnostic anatomic imaging, such as CT or MRI.",{"count":300,"type":20},130,[23],"Background:\n\nPheochromocytoma and paraganglioma are rare tumors. They usually form inside and near the adrenal gland or in the neck region. Not all these tumors can be removed with surgery, and there are no good treatments if the disease has spread. Researchers think a new drug may be able to help.\n\nObjective:\n\nTo learn the safety and tolerability of Lu-177-DOTATATE. Also, to see if it improves the length of time it takes for the cancer to return.\n\nEligibility:\n\nAdults who have an inoperable tumor of the study cancer that can be detected with Ga-68-DOTATATE PET\u002FCT imaging\n\nDesign:\n\nParticipants will be screened with a medical history, physical exam, and blood tests.\n\nEligible participants will be admitted to the NIH Clinical Center.\n\nParticipants will get the study drug in an intravenous infusion. They will get 4 doses, given about 8 weeks apart.\n\nBetween 4 and 24 hours after each study drug dose, participants will have scans taken. They will lie on their back on a scanner table.\n\nParticipants will have vital signs taken. They will give blood and urine samples.\n\nDuring the study, participants will have other scans taken. Some scans will use a radioactive tracer.\n\nParticipants will complete quality of life questionnaires.\n\nParticipants will be contacted by phone 1-3 days after they leave the Clinical Center. They will then be followed every 3 to 6 months for 3 years or until their disease gets worse.",[30,119,120,304],"Neuroendocrine Neoplasms",[306,307,308,309,310],"Hypertension","Catecholamine","Familial Syndromes","Somatostatin Receptors","Ionizing Radiation","2026-04-23",{"date":313,"type":38},"2026-04-24",{"date":315,"type":38},"2017-10-10",{"date":317,"type":20},"2033-01-01",{"name":77,"class":78},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":326,"enrollmentInfo":327,"targetDuration":328,"studyType":277,"phases":4,"briefSummary":329,"conditions":330,"keywords":333,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":4},"100632637","prospective-cohort-study-of-pheochromocytomaparaganglioma-100632637","NCT07516275","Prospective Cohort Study of Pheochromocytoma\u002FParaganglioma","Validation and Extension Study of the Predictive Model for Intraoperative Hemodynamic Instability in Pheochromocytoma\u002FParaganglioma Resection - a Single-center, Prospective, Observational Cohort Study","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosed with pheochromocytoma\u002Fparaganglioma by imaging and laboratory tests and scheduled for elective resection.\n* Planned intraoperative continuous invasive arterial pressure monitoring.\n* Willing and able to provide written informed consent.\n* Able to comply with preoperative CGM monitoring, AI agent assessment, and postoperative follow-up.\n\nExclusion Criteria:\n\n* Intraoperative hemodynamic data missing ≥20%.\n* Postoperative histopathology excludes PPGL diagnosis.\n* Cardiac paraganglioma or metastatic PPGL.\n* Severe cardiac disease (e.g., severe valvular disease, severe heart failure) that could independently cause intraoperative HDI.\n* Pregnancy or breastfeeding.\n* Mental illness, cognitive impairment, or communication barriers that prevent compliance with study procedures.\n* Refusal to undergo CGM monitoring or AI agent assessment.\n* Major illness (e.g., acute myocardial infarction, stroke, severe infection) within 3 months prior to surgery.\n* Severe hepatic or renal insufficiency (Child-Pugh class C, eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²).","99 Years",{"count":208,"type":20},"6 Weeks","The study will enroll patients scheduled for PPGL removal surgery at Peking Union Medical College Hospital. Before surgery, researchers will use a 6-variable model to predict the patient's risk of experiencing severe blood pressure swings during the operation. During surgery, a real-time early warning tool will be tested for its ability to accurately predict blood pressure changes 60 seconds in advance. The study will also explore the value of continuous glucose monitoring (CGM) in understanding blood pressure fluctuations and evaluate the performance of an artificial intelligence (AI) agent for preoperative anesthesia assessment, comparing its accuracy, consistency, and efficiency against that of human anesthesiologists.\n\nParticipation involves no changes to the patient's standard surgical or medical care. It includes collecting clinical data, wearing a CGM sensor from the day before to the day after surgery, and having the preoperative assessment performed by both the AI agent and anesthesiologists.",[30,119,331,332],"Hemodynamic Instability","Intraoperative Complications",[30,119,331,334,335,336,337],"Predictive Model","Artificial Intelligence","Continuous Glucose Monitoring","Prospective Cohort","2026-04-02",{"date":340,"type":38},"2026-04-07",{"date":342,"type":20},"2026-04",{"date":344,"type":20},"2028-02",{"name":346,"class":45},"Peking Union Medical College Hospital",{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":21,"phases":357,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":382},"100371641","phase-1-gene-modified-immune-cells-after-conditioning-regimen-for-the-treatment-of-stage-iiic-or-iv-melanoma-or-metastatic-solid-tumors-100371641","NCT04119024","Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors","Inclusion Criteria:\n\n* Histologically confirmed malignancy that is considered surgically incurable with either:\n\n  * Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis\n  * Stage IV melanoma including patients with known brain metastases\n  * Other metastatic, non-central nervous system (CNS) solid tumor relapsed or refractory after all standard-of-care systemic therapies for which the patient is eligible\n* Confirmed IL13Ralpha2 tumor expression by immunohistochemistry (immunohistochemical assay \\[IHA\\] H-Score \\>= 50 in at least 10% of the total tumor specimen and in at least two high-power fields)\n* Age greater than or equal to 18 years old and less than 75 years old\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* A minimum of one measurable lesion defined as:\n\n  * Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), OR\n  * Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)\n* Absolute neutrophil count (ANC) \\>= 1 x 10\\^9 cells\u002FL (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Platelets \\>= 75 x 10\\^9\u002FL (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Hemoglobin \\>= 9.5 g\u002FdL (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Aspartate and alanine aminotransferases (AST, ALT) =\\\u003C 2.5 x upper limit of normal (ULN) (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Total bilirubin =\\\u003C 2 x ULN (except patients with documented Gilbert's syndrome) (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Creatinine \\\u003C 2 mg\u002FdL (or a glomerular filtration rate \\> 45) (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Patients with melanoma must have progressed following \\>= 1 line of systemic therapy, including immune checkpoint inhibitor and a BRAF inhibitor in combination with MEK inhibitor for patients with BRAF V600-activating mutation and is not considered to have an alternate treatment option with curative intent\n* Must be willing and able to accept at least one leukapheresis procedure (This does not apply for patients receiving a second infusion of IL13R a2 CAR T cells as they will not undergo leukapheresis)\n* Must be willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Inability to purify \\>= 1 x 10\\^7 T cells from leukapheresis product (this does not apply to patients receiving a second infusion of IL13Ra2 CAR T cells as they will not undergo leukapheresis)\n* Previously known hypersensitivity to any of the agents used in this study; known sensitivity to cyclophosphamide or fludarabine\n* Received systemic treatment for cancer, including immunotherapy, within 14 days prior to initiation of conditioning chemotherapy administration within this protocol\n* Clinically active brain metastases. Radiological documentation of absence of active brain metastases at screening is required for all patients. Prior evidence of brain metastasis successfully treated with surgery or radiation therapy will not be exclusion for participation as long as they are deemed under control at the time of study enrollment\n* Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 2 weeks prior to enrollment; not including patients with primary or secondary adrenal insufficiency who require physiologic replacement with steroids, or patients on inhaled or topical steroids at standard doses\n* Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion. If there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and\u002For infectious disease specialist\n* Hepatitis B or C seropositivity with evidence of ongoing liver damage, which would increase the likelihood of hepatic toxicities from the chemotherapy conditioning regimen and supportive treatments. If there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and\u002For infectious disease specialist\n* Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol\n* A Tiffeneau-Pinelli index \\\u003C 70% of the predicted value. Subjects will be excluded if pulmonary function tests indicate they have insufficient pulmonary capability\n* Patients will be excluded if they have a history of clinically significant electrocardiography (ECG) abnormalities, symptoms of cardiac ischemia or arrhythmias and have a left ventricular ejection fraction (LVEF) \\\u003C 45% on a cardiac stress test (stress thallium, stress multigated acquisition scan (MUGA), dobutamine echocardiogram, or other stress test)\n* Patients with ECG results of any conduction delays (PR interval \\> 200 ms, corrected QT (QTC) \\> 480 ms), sinus bradycardia (resting heart rate \\\u003C 50 beats per minute), sinus tachycardia (HR \\> 120 beats per minute) will be evaluated by a cardiologist prior to starting the trial. Patients with any arrhythmias, including atrial fibrillation\u002Fatrial flutter, excessive ectopy (defined as \\> 20 ventricular premature complex \\[PVC\\]s per minute), ventricular tachycardia, 3rd degree heart block will be excluded from the study unless cleared by a cardiologist\n* Pregnancy or breast-feeding. Female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and for 6 months afterwards. All female patients with reproductive potential must have a negative pregnancy test (serum\u002Furine) at screening and again within 14 days from starting the conditioning chemotherapy. The definition of effective contraception will be based on the judgment of the study investigators. Patients who are breastfeeding are not allowed on this study\n* A concomitant active malignancy that would be considered to interfere with the assessment of the primary or secondary endpoints of the study","75 Years",{"count":356,"type":20},18,[59],"This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) that have the ability to kill tumor cells. The T cells are obtained from the patient's own blood, grown in a laboratory, and modified by adding the IL13Ralpha2 CAR gene. The IL13Ralpha2 CAR gene is inserted into T cells with a virus called a lentivirus. The lentivirus allows cells to make the IL13Ralpha2 CAR protein. This CAR has been designed to bind to a protein on the surface of tumor cells called IL13Ralpha2. This study is being done to determine the dose at which the gene-modified immune cells are safe, how long the cells stay in the body, and if the cells are able to attack the cancer.",[360,361,362,363,364,365,366,367,120,119,30,281,368,369,370,371,372],"Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Recurrent Malignant Solid Neoplasm","Refractory Malignant Solid Neoplasm","Uveal Melanoma","Acral Melanoma","Pancreatic Neuroendocrine Tumor","Thyroid Cancer","Breast Cancer","Lung Adenocarcinoma","Head and Neck Squamous Cell Carcinoma","2026-03-13",{"date":375,"type":38},"2026-03-17",{"date":377,"type":38},"2025-10-07",{"date":379,"type":20},"2026-10",{"name":381,"class":45},"Anusha Kalbasi",3,{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":21,"phases":392,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":46},"100488163","early-phase-1-in-vivo-parp-1-expression-with-18f-fluorthanatrace-petct-in-patients-with-pheochromocytoma-and-paraganglioma-100488163","NCT05636540","In Vivo PARP-1 Expression With 18F-FluorThanatrace PET\u002FCT in Patients With Pheochromocytoma and Paraganglioma","Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET\u002FCT) in Patients With Pheochromocytoma and Paraganglioma","Inclusion Criteria:\n\n1. Participants will be ≥ 18 years of age.\n2. Clinical diagnosis of pheochromocytoma or paraganglioma based on biochemical and imaging studies At least one lesion identified on standard of care imaging (e.g. CT, MRI, FDG or 68-Gallium dotatate, other PET\u002FCT or MIBG).\n3. Standard of care germline genetic testing performed for clinical purposes or participant's consent for germline genetic testing for research purposes.\n4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nExclusion Criteria:\n\n1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.\n2. Females who are pregnant or breastfeeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential prior to FTT injection.\n3. Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.",{"count":391,"type":20},30,[393],"EARLY_PHASE1","This study will enroll up to 30 evaluable patients with pheochromocytoma or paraganglioma who are undergoing surgical or systemic treatment.\n\nA pre-treatment 18F-FluorThanatrace (\\[18F\\]FTT) positron emission tomography\u002Fcomputed tomography (PET\u002FCT) scan will be done prior to surgery or systemic therapy.\n\nPET\u002FCT imaging will be used to evaluate PARP-1 expression in sites of pheochromocytoma or paraganglioma using the investigational radiotracer \\[18F\\]FTT. This is an observational study in that \\[18F\\]FTT PET\u002FCT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the \\[18F\\]FTT PET\u002FCT results, treatment decisions will be made by the treating physicians based upon clinical criteria.",[30,119],"2026-02-26",{"date":398,"type":38},"2026-02-27",{"date":400,"type":38},"2023-07-01",{"date":402,"type":20},"2026-12-31",{"name":404,"class":45},"Heather Wachtel",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":412,"targetDuration":414,"studyType":277,"phases":4,"briefSummary":415,"conditions":416,"keywords":440,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":46},"100560175","institutional-registry-of-rare-diseases-100560175","NCT06573723","Institutional Registry of Rare Diseases","Institutional Registries of Rare Diseases at Hospital Italiano de Buenos Aires (HIBA)","Inclusion Criteria:\n\n* Clinical and\u002For molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, or Cushing Syndrome.\n* Must be followed at Hospital Italiano de Buenos Aires.\n\nExclusion Criteria:\n\n\\- Refusal to participate in the study or in the informed consent process.",{"count":413,"type":20},380,"10 Years","The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).\n\nMoreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes.",[417,418,419,420,30,119,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,282,438,439],"Rare Diseases","Amyloidosis","Sarcoidosis","Phacomatosis","Von Hippel-Lindau Disease","Immunoglobulin G4-Related Disease","Demyelinating Diseases","Inborn Errors of Metabolism","Eosinophilic Gastrointestinal Disorders","Hypertrophic Cardiomyopathy","Gaucher Disease","Congenital Adrenal Hyperplasia","Hereditary Angioedema","Pulmonary Hypertension","Wilson Disease","Vascular Anomalies","Mastocytosis","Multiple Endocrine Neoplasia","Inflammatory Bowel Diseases","Prader-Willi Syndrome","Hirschsprung Disease","HHT","Hemorrhagic Hereditary Telangiectasia",[441,442,443,420,444,445,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,282,439],"rare diseases","amyloidosis","sarcoidosis","pheochromocytoma","paraganglioma","2026-01-12",{"date":448,"type":38},"2026-01-14",{"date":450,"type":38},"2024-07-01",{"date":452,"type":20},"2034-12-31",{"name":454,"class":45},"Hospital Italiano de Buenos Aires",{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":461,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":462,"targetDuration":464,"studyType":277,"phases":4,"briefSummary":465,"conditions":466,"keywords":473,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":46},"100298073","genetic-analysis-of-pheochromocytomas-paragangliomas-and-associated-conditions-100298073","NCT03160274","Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions","Inclusion Criteria:\n\n* diagnosis of pheochromocytoma and or paraganglioma\n* family member with diagnosis of pheochromocytoma and or paraganglioma\n* diagnosis of a pheochromocytoma- and or paraganglioma-associated condition\n* family member with diagnosis of a pheochromocytoma- and or paraganglioma-associated condition\n\nExclusion Criteria:\n\n* unconfirmed diagnosis of pheochromocytoma and\u002For paraganglioma or associated condition",true,{"count":463,"type":20},2000,"30 Years","Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma\u002Fparaganglioma of various genetic origins.",[30,119,467,468,469,470,471,472],"Inherited Cancer Syndrome","Associated Conditions","Kidney Neoplasms","Bone Cancer","Thyroid Neoplasms","Other Cancer",[474,475,476,477],"tumor suppressor gene","oncogene","mutation","susceptibility gene","2025-10-13",{"date":480,"type":38},"2025-10-15",{"date":482,"type":38},"2005-10-19",{"date":484,"type":20},"2030-12-31",{"name":486,"class":45},"The University of Texas Health Science Center at San Antonio",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":274,"enrollmentInfo":495,"targetDuration":497,"studyType":277,"phases":4,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":506,"leadSponsor":508,"locationsCount":4},"100608337","cardiovascular-complications-after-adrenalectomy-for-pheochromocytoma-and-non-secreting-tumors-100608337","NCT07200245","Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors","Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors - A Prospective Observational Multicenter European Study (HEMODYNAMICS)","HEMODYNAMICS","Inclusion Criteria:\n\n* Patients undergoing adrenalectomy for pheochromocytoma\n* Patients undergoing adrenalectomy for non-secreting tumors. Patients with non-secreting tumors are those with indication for adrenalectomy in the Eurocrine database corresponding to \" excluding malignancy \".\n\nExclusion Criteria:\n\n* Children and minors (\\\u003C18 years).\n* Pregnant women.\n* Patients with other indication for adrenalectomy in Eurocrine (i.e. Adrenocortical cancer, Cushing, Primary aldosteronism, Metastasis).",{"count":496,"type":20},522,"30 Days","Pheochromocytoma is an adrenomedullary chromaffin cell tumour that releases catecholamines. Adverse cardiovascular events are considered the main cause of morbidity and mortality in patients with pheochromocytoma. Consequently, preoperative medical preparations using alpha-blockers or other antihypertensive drugs and the control of hemodynamic instability during adrenalectomy for pheochromocytoma are recommended by guidelines to prevent vasoconstriction, perioperative cardiovascular complications, and the risk of death. However, the definition of a catecholamine-induced hypertensive crisis in patients with pheochromocytoma has only recently been validated by an international consortium as the occurrence of systolic\u002Fdiastolic blood pressure \\>180\u002F120 mmHg1. Limitations of published studies include small sample sizes, and single institution analysis. Some studies have reported substantial variability in the management of pheochromocytomas, with the use of routine preoperative medical preparation varying from 49% to 100%, whereas others have questioned the utility of this preparation for postoperative cardiovascular complications. The aim of this study was to evaluate pan-European practices in terms of specific preoperative medical preparation before surgery and to identify risk factors for postoperative cardiovascular complications 30 days after adrenalectomy for pheochromocytoma and non-secreting tumors (indication for surgery = \" excluding malignancy \").\n\nThe EUROCRINE® registry offers a valuable opportunity to assess clinical practices for preoperative medical preparation and the morbidity linked to adrenalectomy for pheochromocytoma and non-secreting tumors. This prospective study aims to refine surgical protocols and inform updates to existing guidelines, thereby advancing the management of adrenalectomy for pheochromocytoma.",[30,500,501],"Cardiovascular Complication","Adrenal Incidentaloma","2025-09-22",{"date":504,"type":38},"2025-10-01",{"date":504,"type":20},{"date":507,"type":20},"2027-12-31",{"name":509,"class":45},"Central Hospital, Nancy, France",{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":17,"minAge":517,"maxAge":4,"enrollmentInfo":518,"targetDuration":517,"studyType":277,"phases":4,"briefSummary":519,"conditions":520,"keywords":521,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":46},"100607972","clinical-application-of-somatostatin-receptor-and-norepinephrine-transporter-targeted-imaging-for-diagnosis-and-staging-of-neuroblastoma-and-pheochromocytomaparaganglioma-100607972","NCT07195500","Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma\u002FParaganglioma","the Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for the Diagnosis and Staging of Neuroblastoma and Pheochromocytoma\u002FParaganglioma","Inclusion Criteria:\n\n* Age: ≥6 months (pediatric and adult).\n* Suspected or confirmed diagnosis of neuroblastoma (NB) or pheochromocytoma\u002Fparaganglioma (PPGL).\n* Clinical indication for SSTR and\u002For NET-targeted molecular imaging for initial staging, restaging, suspected recurrence, response assessment, or treatment planning.\n* Ability to undergo PET\u002FCT or PET\u002FMRI and\u002For SPECT\u002FCT per protocol; for the PET\u002FMRI subset, no MRI contraindications.\n* Provision of written informed consent\u002Fassent per local regulations.\n* Women of childbearing potential: negative pregnancy test within 72 hours prior to tracer administration and agreement to use effective contraception during the imaging window.\n* For the multi-tracer subset (if applicable): willingness to undergo two imaging studies within a predefined window (e.g., ≤28 days) without intervening antitumor therapy.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding; breastfeeding participants unwilling to follow tracer-specific lactation interruption guidance per institutional policy.\n* Any condition that, in the investigator's judgment, precludes safe imaging or protocol compliance (e.g., uncontrolled cardiorespiratory disease, severe claustrophobia not amenable to sedation\u002Fanxiolysis).\n* Known hypersensitivity to study radiopharmaceuticals or their excipients.\n* Use of interfering medications without feasible washout:\n\nNET imaging: drugs that affect catecholamine transport\u002Fstorage (e.g., labetalol, tricyclic antidepressants, certain sympathomimetics) per site SOPs.\n\nSSTR imaging: long-acting somatostatin analogues within \\~3-4 weeks or short-acting within \\~24-48 hours, unless clinically unavoidable.\n\n* Prior therapeutic or high-dose 131I-MIBG within a period that would confound diagnostic imaging or dosimetry (e.g., within 6 months), at the investigator's discretion.\n* Contraindications to required modality-specific procedures (e.g., MRI-incompatible implants for PET\u002FMRI; iodinated\u002Fgadolinium contrast contraindication only if contrast is mandated and no alternative pathway is acceptable).\n* Inability to lie still for the required acquisition time and sedation not feasible per institutional policy.\n* Concurrent participation in an interventional study or receipt of anticancer therapy that would confound imaging interpretation within the imaging window; for multi-tracer comparisons, any interval systemic therapy between scans.","6 Months",{"count":391,"type":20},"The goal of this clinical trial is to evaluate the diagnostic efficacy of somatostatin receptor and norepinephrine transporter targeted imaging (including 18F-MFBG, 123I-MIBG, 131I-MIBG, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE, 68Ga-DOTA-TOC, and other radiolabeled somatostatin analogues) in the diagnosis and staging of neuroblastoma and pheochromocytoma\u002Fparaganglioma patients aged 1-70 years. The main questions it aims to answer are:\n\nCan molecular targeted imaging using various norepinephrine transporter tracers (18F-MFBG, 123I\u002F131I-MIBG) and somatostatin receptor tracers (68Ga-DOTA-peptides series) accurately detect primary tumors and metastatic lesions in neuroblastoma\u002Fpheochromocytoma patients? What is the comparative diagnostic performance (sensitivity, specificity, accuracy) of different molecular imaging techniques compared to histopathological diagnosis as the gold standard? Researchers will compare the imaging findings from multiple tracer types with surgical pathology results to assess diagnostic accuracy and clinical staging precision.\n\nParticipants will:\n\n* Undergo screening assessments including medical history, physical examination, and laboratory tests\n* Receive intravenous injection of selected tracers (18F-MFBG, 68Ga-DOTA-NOC\u002FTATE, or other appropriate agents) at standardized doses followed by PET-CT\u002FMRI imaging at optimal time points\n* Undergo histopathological examination within 2 months post-imaging\n* Complete safety follow-up for 6 months to monitor for any adverse reactions to the imaging agents",[212,30,119],[522,97,444,445,523,524],"neuroblastoma","somatostatin receptor","norepinephrine transporter","2025-09-19",{"date":527,"type":38},"2025-09-26",{"date":529,"type":38},"2024-12-25",{"date":531,"type":20},"2028-06-30",{"name":533,"class":45},"Nanjing First Hospital, Nanjing Medical University",{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":541,"enrollmentInfo":542,"targetDuration":4,"studyType":277,"phases":4,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":555},"100578626","18f-mfbg-pet-imaging-in-the-evaluation-of-pheochromocytoma-100578626","NCT06813742","18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma","A Prospective Exploratory Study Evaluating the Diagnostic Usefulness of 18F-mFBG PET Imaging in Pheochromocytoma","Inclusion Criteria:\n\n1. Aged 30-80 years old, primary school or above, with a regular caregiver;\n2. Clinically diagnosed patients with pheochromocytoma;\n3. Can provide informed consent, can understand and comply with the study requirements.\n\nExclusion Criteria:\n\n1. Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system;\n2. Uncontrolled hypertension or high-risk BP (i.e., systolic BP \\> 180 mmHg or diastolic BP \\> 110 mmHg);\n3. Patients with mental disorders or primary affective disorders;\n4. Unable to understand and adhere to the study protocol or provide informed consent;\n5. Contraindications to PET imaging (including pregnant women, lactating women, and women of childbearing age with recent childbearing plans, etc.);\n6. Allergy to imaging agents;\n7. Patients who were unable to cooperate with PET scanning, such as hypoglycemia, severe pain or tremor.","80 Years",{"count":543,"type":20},80,"The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.",[30],"2025-08-06",{"date":548,"type":38},"2025-08-07",{"date":550,"type":38},"2023-05-01",{"date":552,"type":20},"2026-12",{"name":554,"class":45},"First Affiliated Hospital of Zhejiang University",2,{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":21,"phases":565,"briefSummary":567,"conditions":568,"keywords":577,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":46},"100545064","using-the-ehr-to-advance-genomic-medicine-across-a-diverse-health-system-100545064","NCT06377033","Using the EHR to Advance Genomic Medicine Across a Diverse Health System","Using Behavioral Economics and Implementation Science to Advance the Use of Genomic Medicine Utilizing an EHR Infrastructure Across a Diverse Health System","Inclusion Criteria:\n\n* 18 years of age or older\n* diagnosed with one of the study conditions\n\nExclusion Criteria:\n\n* Under 18 years of age\n* not diagnosed with one of the study conditions",{"count":564,"type":20},1000,[566],"NA","Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place.\n\nInnovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and\u002For patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dissemination: In addition to standard dissemination modalities,PheKB95, GitHub and Epic Community Library, the investigators propose to disseminate via AnVIL (NHGRI's Genomic Data Science Analysis, Visualization, and Informatics Lab-Space). Our results will represent an entirely new paradigm for the provision of genomic medicine for patients in whom the results of genetic testing change medical management.",[569,119,30,570,571,572,573,574,575,576],"Genetic Predisposition","ALS","Parkinson Disease","Polyneuropathies","Frontotemporal Dementia","Alzheimer Disease","Cardiomyopathy Non-ischemic","Thoracic Aortic Aneurysm",[578,579,580],"Genetic testing","Genomic medicine","Electronic health record","2025-07-16",{"date":583,"type":38},"2025-07-20",{"date":585,"type":38},"2024-06-10",{"date":587,"type":20},"2027-06-30",{"name":133,"class":45},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":596,"maxAge":597,"enrollmentInfo":598,"targetDuration":4,"studyType":21,"phases":600,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":612,"locationsCount":46},"100493268","phase-4-the-effect-and-safety-of-omitting-preoperative-alpha-adrenergic-blockade-for-normotensive-pheochromocytoma-100493268","NCT05702944","The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma","A Pilot Study for Randomized Controlled Trial on the Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma","Inclusion Criteria:\n\n* Patients aged 19 to 70 years old\n* Patients who consented to the study and obtained consent for the study\n* Patients undergoing unilateral total adrenalectomy due to normotensive pheochromocytoma\u002Fparaganglioma with less than five times of upper limits of serum metanephrine\n\nExclusion Criteria:\n\n* Patients under 18 or over 70 years old\n* Pregnant women\n* Patients with bilateral pheochromocytoma\n* Patients suspected of malignant pheochromocytoma\u002Fparaganglioma or distant metastasis\n* Patients requiring preoperative intensive care unit due to severe hemodynamic instability\n* Patients with hypertension (the blood pressure measured more than two times is constantly greater than 140\u002F90 mmHg) or already taking a antihypertensive medication\n* Patients with a history of coronary artery disease\n* Patients with a history of arrhythmia (atrial fibrillation, Paroxysmal supraventricular tachycardia)\n* Patients with a history of cerebrovascular disease (cerebral aneurysm, cerebral infarction, cerebral hemorrhage)\n* Patients judged unsuitable by the person in charge of the clinical trial","19 Years","70 Years",{"count":599,"type":20},24,[601],"PHASE4","Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors originating from catecholamine producing chromaffin cells in the adrenal medulla and extra-adrenal paraganglia. The overall age-standardized incidence rate is 0.18 per 100,000 person-years in Korea.\n\nThe definitive treatment of PPGL is surgical excision of tumor. However, surgery is associated with a high risk of perioperative hemodynamic instability (HI). To avoid perioperative HI in patients diagnosed with PPGL, preoperative management including routine use of alpha blockade and volume expansion has been advocated by several guidelines.\n\nWhile unstable hypertension and tachycardia should be controlled in patients with PPGL, there is controversial that all patients diagnosed with PPGL should undergo preoperative pharmacological treatment, especially alpha blockade. The most important risk of preoperative alpha blockade use is perioperative hypotension.\n\nA recent study reported that patients diagnosed with PPGL postoperatively may have no further higher risk of intraoperative hypertension than those diagnosed preoperatively despite insufficient preoperatively management of PPGL.\n\nTherefore, it is a very important to study the relationship between HI and preoperative alpha blockade in normotensive patients diagnosed with PPGL. The aim this study is to analyze the effect and safety of omitting preoperative alpha-adrenergic blockade for normotensive pheochromocytoma through a prospective randomized controlled trial. The patients is divided into two groups. The patients in control group take a phenoxybenzamine at least 2 to 5 weeks before surgery. The patients in case group do not take a phenoxybenzamine.\n\nPrimary outcome is to evaluate the percentage of time during surgery with systolic blood pressure more than 160mmHg or average blood pressure less than 60mmHg. And secondary outcomes are to evaluate hemodynamic instability in preoperative ward and postoperative ward.",[30,119,604,605],"Adrenalectomy; Status","Adrenergics Causing Adverse Effects in Therapeutic Use","2025-06-09",{"date":608,"type":38},"2025-06-12",{"date":610,"type":38},"2023-01-18",{"date":507,"type":20},{"name":613,"class":45},"Seoul National University Hospital",{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":4,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":354,"enrollmentInfo":621,"targetDuration":4,"studyType":21,"phases":623,"briefSummary":624,"conditions":625,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":46},"100549083","phase-2-anlotinib-combined-with-benmelstobart-for-advanced-pheochromocytoma-100549083","NCT06429397","Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma","A Single-arm, Multicenter, Prospective Phase II Clinical Study of Anlotinib Combined With Benmelstobart in the First-line Treatment of Advanced Pheochromocytoma\u002FParaganglioma","Inclusion Criteria:\n\n* Patients voluntarily participate in this study and sign informed consent;\n* Patients aged ≥18 years and ≤75 years;\n* ECOG score ≤2 points; Expected survival ≥6 months;\n* Pathological diagnosis of advanced pheochromocytoma\u002Fparaganglioma: including clinical stage IV unresectable pheochromocytoma\u002Fparaganglioma with postoperative recurrence or metastasis;\n* Unwilling or unsuitable for chemotherapy and radionuclide therapy.\n* At least one measurable lesion (RECIST 1.1);\n* The main organs function well, and the laboratory examination indicators meet:\n\n  1. Blood routine examination:\n\n     Hemoglobin (HB) ≥ 90g\u002FL(5.6 mmol\u002FL); Absolute neutrophil count (ANC) ≥1.5×109\u002FL; Total white blood cells ≥3.5×109\u002FL;\n\n     ③ Platelet (PLT) ≥ 80×109\u002FL;\n\n     Blood biochemical examination:\n\n     ① Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN (liver metastasis\u002Fbone metastasis ≤5 × ULN; Bone metastases ≤5 ULN);\n\n     ② Serum total bilirubin (TBIL) ≤1.5 × ULN;\n\n     ③ Serum creatinine Cr≤1.5×ULN or creatinine clearance ≥60 ml\u002Fmin; Blood urea nitrogen (BUN)≤2.5 × upper limit of normal value (ULN);\n\n     ④ Albumin (ALB)≥30 g\u002FL;\n  2. Blood clotting test:\n\n     * Activated partial thromboplastin time (APTT), International standardized ratio (INR), prothrombin time (PT) ≤ 1.5×ULN;\n* Women of reproductive age must confirm their non-pregnant status before enrollment, and all enrolled subjects (whether male or female) should take adequate contraceptive measures during the entire treatment period and within 4 weeks after the end of treatment;\n* The subjects voluntarily joined the study and were willing to return to the hospital for follow-up, and the compliance was good; Myocardial enzymes and ejection fraction were normal.\n\nExclusion Criteria:\n\n* known allergic reactions to anrotinib hydrochloride capsules, Benmelstobart active ingredients or any excipients;\n* Receiving anti-tumor monoclonal antibodies or other investigational drugs before enrollment; Previous treatment with other anti-PD-1 monoclonal antibodies or other medications targeting PD-1 \u002F PD-L1;\n* previous use of anrotinib hydrochloride capsules or other anti-angiogenic drugs, such as Sunitinib, bevacizumab, etc.;\n* Patients were taking immunosuppressants or systemic hormone therapy for immunosuppressive purposes (doses greater than 10mg\u002Fday prednisone or other equivalent hormones) and were still taking them within 2 weeks prior to enrollment;\n* The patient has any active autoimmune disease or a history of autoimmune disease; Have clinical symptoms or diseases of the heart that are not well controlled;\n* Congenital or acquired immune deficiency;\n* History of gastrointestinal perforation or open biopsy within 4 weeks prior to enrollment; ≥CTCAE grade 3 for any bleeding event, presence of unhealed wounds, ulcers, or fractures;\n* Hyperarterial\u002Fvenous thrombosis events occurred within 6 months before the study period, such as non-cardiovascular and cerebrovascular events (including temporary ischemic attack), deep vein thrombosis (except venous thrombosis caused by intravenous catheterization during previous chemotherapy and cured by investigators), pulmonary embolism, etc.; Cardiac angioplasty or coronary bypass surgery for unstable arrhythmia, unstable angina pectoris or myocardial infarction;\n* People with active bleeding or bleeding tendency;\n* Correcting QT interval \\> 480msec; If a patient has QT interval prolongation, but the cause of the prolongation is assessed by the investigator as a pacemaker (and no other cardiac abnormalities), the patient should be considered suitable for inclusion in the study after discussion with the sponsor study physician;\n* Patients suspected of having other primary cancers; Patients with other primary malignancies within the 5 years prior to the study (other than adequately treated cervical or skin cancer in situ, such as basal cell carcinoma, squamous cell carcinoma, or non-melanoma skin cancer);\n* Combined diseases\u002Fmedical history:\n\n  1. Clinically significant hemoptysis (\\> 50ml daily hemoptysis) occurred within 3 months prior to enrollment; Or clinically significant bleeding symptoms or definite bleeding tendencies, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, stool occult blood or above at baseline, or vasculitis;\n  2. hypertension, which is not well controlled by antihypertensive drugs (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100mmHg); In the 6 months prior to randomization, the following conditions had occurred: myocardial infarction, severe\u002Funstable angina pectoris, NYHA grade 2 or higher cardiac dysfunction, clinically significant supracentricular or ventricular arrhythmias, and symptomatic congestive heart failure;\n  3. interstitial lung disease, non-infectious pneumonia or uncontrollable systemic diseases (such as poorly controlled diabetes (fasting blood glucose (FBG) \\> 10mmol\u002F L), pulmonary fibrosis and acute pneumonia, etc.); Renal failure requires hemodialysis or peritoneal dialysis; Liver cirrhosis, decompensated liver disease, active hepatitis (hepatitis B, defined as HBV-DNA ≥ 500 IU\u002Fml; Hepatitis C, defined as HCV-RNA above the lower detection limit of analytical methods) or chronic hepatitis requiring antiviral therapy;\n\n  (6) Live attenuated vaccine vaccination history within 28 days prior to the first study or live attenuated vaccine vaccination expected during the study period; (7) Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); Combined with hepatitis B and hepatitis C co-infection; Severe infection, including but not limited to bacteremia requiring hospitalization, severe pneumonia, etc. within 4 weeks before the first dose; Active infection of CTCAE grade ≥2 requiring systemic antibiotic treatment within 2 weeks prior to first administration, or unexplained fever \\>38.5°C during screening\u002Fprior to first administration (fever due to tumor, as determined by the investigator, was eligible for inclusion); Evidence of active tuberculosis infection within 1 year prior to administration; Major surgery within 28 days prior to randomization (tissue biopsy required for diagnosis and insertion of a central venous catheter through peripheral venipentesis \\[PICC\\] or infusion PORT is permitted);\n* Participants who have previously received or are preparing to receive allogeneic bone marrow transplantation or solid organ transplantation;\n* Peripheral neuropathy ≥ grade 2; Patients with active brain metastases, malignant meningitis, spinal cord compression, or imaging CT or MRI findings of brain or pia disease during screening (patients with brain metastases who have completed treatment 14 days before enrollment and whose symptoms are stable can be enrolled, but only after brain MRI, CT or venography evaluation to confirm no symptoms of cerebral hemorrhage);\n* significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea, and presence of clinically significant intestinal obstruction.\n* Women who are pregnant, breastfeeding, planning to become pregnant during the study period, or men or women who are fertile but do not want to use appropriate contraceptive methods.\n* The presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participating in the study or interfere with the study results, and patients who are deemed by the investigato\n* not suitable for participation in the study;\n* Patients with brain metastasis;\n* Imaging shows that the tumor has invaded important blood vessels, or follow-up shows that the tumor is highly likely to invade important blood vessels and cause fatal bleeding;\n* Drugs that interact with anlotinib hydrochloride capsules\u002Fpiamplizumab are being used;",{"count":622,"type":20},22,[23],"There is currently no standard first-line treatment for stage PPGL, and the 5-year survival rate of patients with advanced pheochromocytoma\u002Fparaganglioma (PPGL) is low, ranging from 30% to 60%. At present, several domestic teams have carried out clinical studies on the treatment of advanced PPGL with good efficacy. In the early stage, our center used anrotinib to treat advanced PPGL, and the overall effective rate reached 44%. In the early stage, our team used anrotinib combined with PD-1 monoclonal antibody to treat advanced PPGL patients. The effective rate reached 66% (2\u002F3). Therefore, the investigators plan to further conduct prospective studies to explore the efficacy and safety of anlotinib combined with PD-1 monoclonal antibody in the treatment of advanced PPGL, so as to bring benefits to patients with advanced PPGL.",[30],"2025-04-24",{"date":628,"type":38},"2025-04-29",{"date":630,"type":20},"2025-05-01",{"date":632,"type":20},"2027-05-28",{"name":634,"class":45},"Sun Yat-sen University",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":461,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":277,"phases":4,"briefSummary":644,"conditions":645,"keywords":646,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":46},"100550248","hereditary-pheochromocytoma-assessment-of-tumour-immunologies-100550248","NCT06444607","Hereditary Pheochromocytoma Assessment of Tumour Immunologies","HEPHESTOS - Hereditary Pheochromocytoma Assessment of Tumour Immunologies","HEPHESTOS","Inclusion Criteria:\n\nPart I:\n\n* Newly diagnosed patients with PPGL or newly diagnosed patients with (metastatic) PPGL recurrence.\n* OR patients with mutations which predispose for the development of PPGL.\n* Aged \\> 18 years.\n\nPart II:\n\n* Confirmed PPGL on pathology.\n* Aged \\> 18 years.\n\nExclusion Criteria:\n\n* Unable to provide informed consent.\n* Active inflammatory or infectious comorbidities.\n* Other malignancies which are under active treatment (except for basal cell carcinoma, other in situ carcinomas).\n* Using medication interfering with the immune system\n* Pregnancy or breastfeeding\n* A self-reported alcohol consumption of \\>21 units per week",{"count":208,"type":20},"In this study, the investigators are examining the role of the immune system in pheochromocytoma and paraganglioma. The investigators aim to examine the differences in the immune system between people who have these tumors with and without a hereditary predisposition. The investigators also want to see how the immune system changes during the development of the tumor in people with a hereditary predisposition. Finally, the investigators will compare the data with a control group of people without these tumors. Ultimately, the investigators hope that the results will contribute to the discovery of new immune system-targeted medications for pheochromocytoma and paraganglioma.",[30,119],[30,119,647,648],"Tumor microenvironment","Innate immunity","2024-11-18",{"date":651,"type":38},"2024-11-21",{"date":653,"type":38},"2024-06-01",{"date":655,"type":20},"2029-06-01",{"name":657,"class":45},"Radboud University Medical Center",{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":664,"eligibilityCriteria":665,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":666,"targetDuration":4,"studyType":21,"phases":668,"briefSummary":669,"conditions":670,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":555},"100519569","phase-2-receptor-radionuclide-therapy-with-177lu-dotatoc-100519569","NCT06045260","\"Receptor Radionuclide Therapy With 177Lu-DOTATOC","\"Receptor Radionuclide Therapy With 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in SSTR Positive Patients: a Multicenter, Prospective, Phase II Trial\"","LUFOR","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Patients must have histologically or cytologically confirmation of neuroendocrine tumors or any other tumor histology type documented as sst2-positive, that may benefit from receptor radionuclide therapy and for which there are not any other effective treatments, included locoregional methods of control for PPGLs\u002Fpheochromocytoma. For cerebral and PPGLs sst2- positive tumors, if biopsy is no feasible for technical reason or risk benefit balance, patients may be enrolled if CT or MRI strongly suggest oncological lesion confirming the 68Ga PET-CT dota-peptide SSTr2 positivity.\n3. Measurable disease according to RECIST 1.1 criteria also patients without measurable but with evaluable disease can be enrolled.\n4. Any disease stage is allowed. Patients with documented disease will be admitted to the therapeutic phase only if the diagnostic PET\u002FCT 68Ga-peptide images demonstrate a significant uptake in the tumour, according to the adapted Krenning Scale. Only patients with a greater caption (Grade 3 or 4) in most of the lesions will be admitted.\n5. Patients with progressive disease in pre-study period (PD within the last 12 months), refractory to conventional standard treatments; clinical progression is allowed.\n6. Patients with or without concurrent therapy with somatostatin analogs. It will be maintained the same dose of the SSA analogs as at the time of demonstrated disease progression.\n7. Life expectancy of greater than 6 months.\n8. ECOG performance status \\\u003C2.\n9. Adequate haematological, liver and renal function: haemoglobin \\>= 9 g\u002FdL, absolute neutrophil count (ANC) \\>= 1.5 x 109 \u002FL, platelets \\>= 100 x 109 \u002FL, bilirubin ≤1.5 X UNL (upper normal limit), ALT and AST \\\u003C2.5 X UNL (\\\u003C 5 X UNL in presence of liver metastases), creatinine \\\u003C 2 mg\u002FdL and\u002For eGFR or creatinine clearance \\> 50 ml\u002Fmin.\n10. If female of childbearing potential highly effective birth control methods, according to guideline \"Recommendation related to contraception and pregnancy testing in clinical trials\", (2014\\_09\\_15 section 4.1) are mandatory (see Appendix F). Highly effective birth control methods are required beginning at the screening visit and continuing until 6 months following last treatment with study drug. A negative serum pregnancy test should be performed the same day the treatment is started at any cycle. Male patient and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 6 months after final study drug administration. Two acceptable methods of birth control thus include Condom (barrier method of contraception) and one of the following is required (established use of oral, or injected or implanted hormonal method of contraception by the female partner; placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female partner; additional barrier method like occlusive cap with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository in the female partner; tubal ligation in the female partner; vasectomy or other procedure resulting in infertility (eg, bilateral orchiectomy), for more than 6 months (see Appendix F).\n11. Participant is willing and able to give informed consent for participation in the study.\n\nExclusion Criteria:\n\n1. Patients treated with chemotherapy and therapeutic radiotherapy within 4 weeks and treated within 2 weeks with palliative radiotherapy, hormonal or biological therapy.\n2. Known hypersensitivity to lutetium-177 (177Lu), edotreotide, DOTA or components of the formulation or other radiolabeled peptide agents.\n3. Known hypersensitivity to lysine, arginine, or any excipient of the nephroprotective aminoacids given concurrently with the lutetium (177Lu) edotreotide infusion;\n4. Patients treated with prior external beam radiation therapy (EBRT) to more than 25% of the bone marrow.\n5. Patients treated with previous PRRT with an absorbed dose to the kidney more than 23 Gy and more than 1.8 Gy for the bone marrow or as surrogate of dosimetry (13).\n6. Patients which are included in the indication of LUTATHERA®(9).\n7. All acute toxic effects of any prior therapy (including surgery, radiation therapy, chemotherapy) must have resolved to a grade ≤ 1 according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE).\n8. ECOG performance status \\>2.\n9. Participation in another clinical trial with any investigational agents within 30 days prior to study screening.\n10. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n11. Pregnant or breastfeeding women are excluded from the present study.",{"count":667,"type":20},100,[23],"Peptide receptor radionuclide therapy (PRRT) may be recommended in G1- G2 GEP-NET patients with disease progression on somatostatine analogues therapy (LUTATHERA®). However, there are several diseases, including neuroendocrine neoplasia not originating from the digestive tract, for which the efficacy of PRRT has already been demonstrated, but which are not currently within the indications of LUTATHERA and therefore cannot benefit from it (i.e. bronchopulmonary, ovarian, renal NETs and neuroendocrine carcinomas). Moreover, the role of PRRT is also accepted in Pheochromocytomas and paragangliomas (PPGLs), Meningiomas, but also as a salvage therapy in pre-treated NET pts, and other SSTR-positive malignancies (Lymphomas, Gliomas…). Least explored among radiopharmaceuticals for SSTR-positive tumors is 177Lu-DOTATOC. This study aims to investigate the efficacy and safety of lutetium (177Lu) edotreotide (Lu-Dotatoc) on all the above-mentioned diseases that could benefit from receptor radionuclide therapy. We believe that this study, which will involve only patients outside the indication of LUTATHERA, will expand the current knowledge of radionuclide receptor therapy with 177Lu- DOTATOC, particularly with regard to objective response and safety parameters, and may consolidate its in the management of these diseases.",[120,119,30],"2024-08-09",{"date":673,"type":38},"2024-08-13",{"date":675,"type":38},"2023-09-13",{"date":677,"type":20},"2027-01",{"name":679,"class":45},"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS",{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":684,"acronym":4,"eligibilityCriteria":685,"healthyVolunteers":461,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":686,"targetDuration":4,"studyType":277,"phases":4,"briefSummary":688,"conditions":689,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":712,"lastUpdatePostDateStruct":713,"startDateStruct":715,"completionDateStruct":717,"leadSponsor":719,"locationsCount":382},"100556321","genetic-bases-of-neuroendocrine-neoplasms-in-mexican-patients-100556321","NCT06523582","Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients","Inclusion Criteria:\n\nAdult patients with a new or previous clinical diagnosis of any of the following conditions:\n\n* Isolated NENs with sporadic presentation, including bronchopulmonary NENs, gastrointestinal NENs, medullary thyroid carcinoma, pancreatic NENs, paragangliomas, pheochromocytomas, pituitary neuroendocrine tumors, and primary hyperparathyroidism.\n* Familial isolated NENs, including familial isolated pituitary adenoma, familial pheochromocytomas and paragangliomas, familial primary hyperparathyroidism, familial gastrointestinal stromal tumors and X-linked acrogigantism.\n* Clinical syndromes encompassing NENs, with familial or sporadic presentation, including Carney complex, Carney-Stratakis syndrome, Carney triad, Cowden syndrome, DICER1 syndrome, Li-Fraumeni syndrome, Lynch syndrome, multiple endocrine neoplasia type 1, multiple endocrine neoplasia type 2, multiple endocrine neoplasia type 4, neurofibromatosis type 1, Pacak-Zhuang syndrome, paraganglioma, pheochromocytoma and pituitary adenoma syndrome, tuberous sclerosis complex, Von Hippel Lindau syndrome.\n\nExclusion criteria:\n\n* Age \\\u003C18 years.\n* Refusal to give informed consent.",{"count":687,"type":20},750,"Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs. Their clinical behavior is quite variable, encompassing both benign lesions and aggressive tumors that invade surrounding and\u002For distant structures. NENs may also cause serious morbidity due to hormone oversecretion. NENs are among the most frequently inherited human tumors, presenting either isolated or as part of syndromes in which a single patient or family develops multiple tumors. There are also non-inherited changes in the genetic information of the tumor cells that are potential targets for treatment. Both inherited and non-inherited DNA defects can be identified using modern routine genetic tests which, unfortunately, are not widely available in Mexico.\n\nThis project seeks to uncover the genetic defects causing NENs in a large cohort of Mexican patients, using three different methods for genetic testing. Adult individuals with various types of NENs from two reference hospitals in Mexico City will be invited to participate. After completing informed consent, blood and, if possible, tissue samples will be obtained from all participants. Clinical details, laboratory results, imaging studies, and histopathological data at disease presentation will be retrieved.\n\nAn initial screening will be performed by analyzing changes in the sequence of multiple genes that have been associated with the occurrence of NENs. In cases with negative screening, a specific method to assess changes in the number of copies of the same genes will also be employed. Finally, sequences of all DNA regions encoding information required to make proteins will be obtained in selected cases. Analyses will be carried out in blood and, if available, also in tumor tissue samples from study participants. Screening of additional family members will be offered.\n\nThis project will accurately describe the repertoire of specific defects causing NENs in the study population, and will likely uncover and characterize novel genetic associations. The results will contribute for a better understanding of the alterations within and outside known driver genes that shape syndromic presentations, tumor behaviors, and inheritance patterns in individuals with NENs. These data will contribute to improve the information on the molecular bases of NENs, including alterations that can be used as therapeutic targets.",[690,691,692,693,694,695,121,119,30,696,697,698,699,700,701,702,703,704,705,706,707,421,708,709,710,711],"Neuroendocrine Neoplasm","Neuroendocrine Neoplasm of Gastrointestinal Tract","Neuroendocrine Neoplasm of Lung","Thymic Neuroendocrine Neoplasm","Neuroendocrine Tumor of Pancreas","Gastrointestinal Stromal Tumors","Primary Hyperparathyroidism","Pituitary Tumor","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Multiple Endocrine Neoplasia Type 4","Carney Complex","Carney Stratakis Dyad","Carney Triad","Cowden Syndrome","DICER1 Syndrome","Li-Fraumeni Syndrome","Lynch Syndrome","Familial Isolated Pituitary Adenoma","X-Linked Acrogigantism","Neurofibromatosis 1","Tuberous Sclerosis","2024-07-22",{"date":714,"type":38},"2024-07-26",{"date":716,"type":38},"2022-08-03",{"date":718,"type":20},"2037-03-01",{"name":720,"class":45},"Universidad Nacional Autonoma de Mexico",{"id":722,"slug":723,"hasResults":12,"nctId":724,"briefTitle":725,"officialTitle":725,"acronym":4,"eligibilityCriteria":726,"healthyVolunteers":12,"sex":17,"minAge":727,"maxAge":728,"enrollmentInfo":4,"targetDuration":4,"studyType":729,"phases":4,"briefSummary":730,"conditions":731,"keywords":732,"overallStatus":736,"whyStopped":4,"lastUpdateSubmitDate":737,"lastUpdatePostDateStruct":738,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":740,"locationsCount":46},"100286991","a-compassionate-useexpanded-access-protocol-using-131i-mibg-therapy-for-patients-with-refractory-neuroblastoma-and-metastatic-pheochromocytoma-100286991","NCT03015844","A Compassionate Use\u002FExpanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma","Inclusion Criteria:\n\n* Diagnosis: Relapsed\u002FRefractory neuroblastoma, with an original diagnosis made histologically or from elevated urine catecholamines with abnormal tumor cells in bone marrow OR relapsed\u002Frefractory pheochromocytoma.\n* Disease status: Progressive disease at any time (defined as any new lesion or an increase in size by \\>25% of pre-existing disease), or a failure to respond to standard therapy. Patients must have evidence of MIBG uptake into tumor at ≥ one site within 6 weeks prior to entry on study and subsequent to any intervening therapy\n* Prior therapy: A minimum of two weeks since should have elapsed since any chemotherapy causing myelosuppression. It must be a minimum of three months since receiving radiation to any of the following fields: craniospinal, total abdominal, whole lung, total body irradiation. For any other sites of radiation, at least 2 weeks should have elapsed. For patients who received radiation to the only site of MIBG-avid disease within two months of study entry, biopsy confirmation of residual active disease is required, with positive bone marrow being sufficient. At least 7 days should have elapsed since completion of therapy with a biologic agent and at least 3 half-lives should have elapsed since therapy with a monoclonal antibody. No cytokine therapy may be given within 24 hours of receiving 131I-MIBG. Patients may have received prior MIBG therapy, provided they demonstrated a response or stable disease initially, with progressive disease occurring at least 35 days following treatment.\n* Organ function: ANC \\>500\u002FuL, platelets \\>20,000\u002FuL with transfusion allowed. Bilirubin ≤2x ULN, AST\u002FALT ≤10x ULN.Serum Creatinine ≤2x ULN OR 24-hour creatinine clearance OR GFR ≥60ml\u002Fmin\u002F1.73m2. Normal lung function demonstrated by no dyspnea, exercise intolerance or oxygen requirement. Oxygen saturation ≥94% on room air. No clinically significant cardiac dysfunction and ejection fraction ≥45% on echocardiogram.\n* Stem cells: Patients must have a minimum of 2.0 x106\u002Fkg viable CD34+ peripheral blood stem cells for re-infusion following 131I-MIBG. An additional back-up of 2.0x106\u002Fkg CD34+ cells is recommended but not required.\n* Life expectancy longer than 8 weeks,Karnofsky or Lansky performance status of ≥ 50%\n\nExclusion Criteria:\n\n* Pregnant or lactating patients\n* Disease of any organ system that would compromise the patient's ability to participate in the study, including hemodialysis. Significant organ impairment should be discussed with the Principal Investigator prior to study entry\n* Patients with active grade 3-4 infection, as defined by the NCI CTCAE V4.0.\n* Patients with known MBIG-avid brain parenchymal disease (leptomeningeal or skull based metastases are eligible).\n* In patients with metastatic pheochromocytoma, a urinalysis must be preformed prior to study enrollment. If proteinuria is present, a 24 hour urine must be collected and total protein determined. If the 24-hour urine protein is above the institutional upper limit of normal, the patient is excluded.","365 Days","29 Years","EXPANDED_ACCESS","This is an expanded access protocol\u002Fcompassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Response rate, toxicity, and time to progression and death will be evaluated.",[212,30],[733,734,735,522,444],"MIBG","131I-MIBG","relapsed","AVAILABLE","2024-07-03",{"date":739,"type":38},"2024-07-05",{"name":741,"class":45},"Northwell Health",{"id":743,"slug":744,"hasResults":12,"nctId":745,"briefTitle":746,"officialTitle":747,"acronym":4,"eligibilityCriteria":748,"healthyVolunteers":12,"sex":17,"minAge":206,"maxAge":541,"enrollmentInfo":749,"targetDuration":4,"studyType":21,"phases":751,"briefSummary":752,"conditions":753,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":755,"lastUpdatePostDateStruct":756,"startDateStruct":758,"completionDateStruct":760,"leadSponsor":761,"locationsCount":46},"100444575","early-phase-1-18f-mfbg-petct-in-the-evaluation-of-neural-crest-tumor-100444575","NCT05069220","18F-MFBG PET\u002FCT in the Evaluation of Neural Crest Tumor","A Study of 18F-MFBG Imaging for the Tumor Burden Evaluation or Diagnostic Performance in Pheochromocytoma, Paraganglioma and Neuroblastoma.","Inclusion Criteria:\n\n\\- The subject has read, signed, and dated an informed consent form (ICF) prior to any study procedures being performed. Patients with histologically confirmed or clinically suspicious neural crest tumor.\n\nFor patients with neuroblastoma, subject should have a routine clinical 123I-MIBG scintigraphy (planar + SPECT\u002FCT) performed within 6 months prior to the inclusion visit or scheduled within 3 months after the inclusion visit.\n\nThe subject is male or is a nonpregnant, nonlactating female who is either surgically sterile or is post-menopausal. The subject is able and willing to comply with all study procedures as described in the protocol.\n\nExclusion Criteria:\n\n\\- Patients are potentially pregnant (serum and urinary hCG test will be performed in women where pregnancy is not excluded) or is breast-feeding.\n\nPatients undergo surgery between the selection and inclusion visit. Patients who are pregnant, may possibly be pregnant, or wish (including their partners) to become pregnant during the study period, or are lactating. Patients who are not suitable to participate in the trial according to researchers.",{"count":750,"type":20},150,[393],"The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and paraganglioma (PPGL) and neuroblastoma (NB).",[754,212,30,119],"Neuroendocrine Tumor","2024-02-28",{"date":757,"type":38},"2024-03-01",{"date":759,"type":38},"2021-09-01",{"date":552,"type":20},{"name":346,"class":45}]